Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels

Bone

Volumn 46, Issue 4, 2010, Pages 985-992

  Warden, Stuart J ^a,c,e   Hassett, Sean M ^a   Bond, Julie L ^a   Rydberg, Johanna ^a   Grogg, Jamie D ^a   Hilles, Erin L ^a   Bogenschutz, Elizabeth D ^a   Smith, Heather D ^a   Fuchs, Robyn K ^a,b   Bliziotes, M Michael ^c,d   Turner, Charles H ^e  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e Indiana University Purdue University Indianapolis   (United States)

Author keywords

Antidepressant; Depression; Fluoxetine; Osteoporosis; Prozac

Indexed keywords

ANTIDEPRESSANT AGENT; BETA CATENIN; DESIPRAMINE; FLUOXETINE; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; MOOD STABILIZER; NORADRENALIN TRANSPORTER; PSYCHOTROPIC AGENT; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; WNT PROTEIN;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CAGE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG RESEARCH; DRUG TARGETING; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; FEMUR; IMMOBILIZATION; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PHYSICAL ACTIVITY; SIGNAL TRANSDUCTION; SPINE; WEIGHT BEARING;

ABSORPTIOMETRY, PHOTON; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMANIC AGENTS; BONE DENSITY; BONE REMODELING; COMPRESSIVE STRENGTH; DESIPRAMINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR; FLUOXETINE; HINDLIMB SUSPENSION; LITHIUM CHLORIDE; MICE; MOTOR ACTIVITY; RANDOM ALLOCATION; SEROTONIN; SPINE;

EID: 77950532014     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.12.031     Document Type: Article

References (43)

1. Arroll B., Macgillivray S., Ogston S., Reid I., Sullivan F., Williams B., et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann. Fam. Med. 2005, 3:449-456.
2. Hetrick S., Merry S., McKenzie J., Sindahl P., Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst. Rev. 2007, CD004851.
3. Storosum J.G., Wohlfarth T., Schene A., Elferink A., van Zwieten B.J., van den Brink W. Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode. Bipolar. Disord. 2007, 9:793-798.
4. Vestergaard P. Skeletal effects of central nervous system active drugs: anxiolytics, sedatives, antidepressants, lithium and neuroleptics. Curr. Drug Saf. 2008, 3:185-189.
5. Haney E.M., Warden S.J. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J. Musculoskelet. Neuronal. Interact. 2008, 8:133-145.
6. Bolton J.M., Metge C., Lix L., Prior H., Sareen J., Leslie W.D. Fracture risk from psychotropic medications: a population-based analysis. J. Clin. Psychopharmacol. 2008, 28:384-391.
7. Vestergaard P., Rejnmark L., Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos. Int. 2006, 17:807-816.
8. Vestergaard P., Rejnmark L., Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif. Tissue Int. 2008, 82:92-101.
9. Ziere G., Dieleman J.P., van der Cammen T.J., Hofman A., Pols H.A., Stricker B.H. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J. Clin. Psychopharmacol. 2008, 28:411-417.
10. Vestergaard P., Rejnmark L., Mosekilde L. Reduced relative risk of fractures among users of lithium. Calcif. Tissue Int. 2005, 77:1-8.
11. Mezuk B., Eaton W.W., Golden S.H. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos. Int. 2008, 19:1-12.
12. Diem S.J., Blackwell T.L., Stone K.L., Yaffe K., Haney E.M., Bliziotes M.M., et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch. Intern. Med. 2007, 167:1240-1245.
13. Haney E.M., Chan B.K., Diem S.J., Ensrud K.E., Cauley J.A., Barrett-Connor E., et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med. 2007, 167:1246-1251.
14. Landi F., Onder G., Cesari M., Barillaro C., Russo A., Bernabei R. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J. Gerontol. A. Biol. Sci. Med. Sci. 2005, 60:622-626.
15. Thapa P.B., Gideon P., Cost T.W., Milam A.B., Ray W.A. Antidepressants and the risk of falls among nursing home residents. N. Engl. J. Med. 1998, 339:875-882.
16. Battaglino R., Fu J., Spate U., Ersoy U., Joe M., Sedaghat L., et al. Serotonin regulates osteoclast differentiation via its transporter. J. Bone Miner. Res. 2004, 19:1420-1431.
17. Bliziotes M., Eshleman A., Burt-Pichat B., Zhang X.W., Hashimoto J., Wiren K., et al. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 2006, 39:1313-1321.
18. Bliziotes M.M., Eshleman A.J., Zhang X.W., Wiren K.M. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 2001, 29:477-486.
19. Gustafsson B.I., Thommesen L., Stunes A.K., Tommeras K., Westbroek I., Waldum H.L., et al. Serotonin and fluoxetine modulate bone cell function in vitro. J. Cell. Biochem. 2006, 98:139-151.
20. Westbroek I., van der Plas A., de Rooij K.E., Klein-Nulend J., Nijweide P.J. Expression of serotonin receptors in bone. J. Biol. Chem. 2001, 276:28961-28968.
21. Yadav V.K., Ryu J.H., Suda N., Tanaka K.F., Gingrich J.A., Schutz G., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837.
22. Warden S.J., Haney E.M. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies. J. Musculoskelet. Neuronal. Interact. 2008, 8:121-132.
23. Warden S.J., Robling A.G., Sanders M.S., Bliziotes M.M., Turner C.H. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005, 146:685-693.
24. Warden S.J., Nelson I.R., Fuchs R.K., Bliziotes M.M., Turner C.H. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 2008, 15:1176-1183.
25. Bonnet N., Bernard P., Beaupied H., Bizot J.C., Trovero F., Courteix D., et al. Various effects of antidepressant drugs on bone microarchitecture, mechanical properties and bone remodeling. Toxicol. Appl. Pharmacol. 2007, 221:111-118.
26. Clement-Lacroix P., Ai M., Morvan F., Roman-Roman S., Vayssiere B., Belleville C., et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17406-17411.
27. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 1997, 283:1305-1322.
28. Cryan J.F., O'Leary O.F., Jin S.H., Friedland J.C., Ouyang M., Hirsch B.R., et al. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8186-8191.
29. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
30. Alvarez J.C., Gluck N., Fallet A., Gregoire A., Chevalier J.F., Advenier C., et al. Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor for antidepressant response?. Psychopharmacology 1999, 143:97-101.
31. Ferguson J.M., Hill H. Pharmacokinetics of fluoxetine in elderly men and women. Gerontology 2006, 52:45-50.
32. Quiroz J.A., Gould T.D., Manji H.K. Molecular effects of lithium. Mol. Interv. 2004, 4:259-272.
33. Holmes A., Yang R.J., Murphy D.L., Crawley J.N. Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 2002, 27:914-923.
34. Morey-Holton E.R., Globus R.K. Hindlimb unloading of growing rats: a model for predicting skeletal changes during space flight. Bone 1998, 22:83S-88S.
35. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 2005, 29:571-625.
36. Yadav V.K., Oury F., Suda N., Liu Z.W., Gao X.B., Confavreux C., et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138:976-989.
37. Zolkowska D., Baumann M.H., Rothman R.B. Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. J. Pharmacol. Exp. Ther. 2008, 324:791-797.
38. Westbroek I., Waarsing J.H., van Leeuwen J.P., Waldum H., Reseland J.E., Weinans H., et al. Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats. J. Cell. Biochem. 2007, 101:360-368.
39. Warden S.J., Robling A.G., Haney E.M., Turner C.H., Bliziotes M.M. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 2010, 46:4-12.
40. Dawson L.A., Nguyen H.Q., Smith D.L., Schechter L.E. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. J. Psychopharmacol. 2002, 16:145-152.
41. Koch S., Perry K.W., Nelson D.L., Conway R.G., Threlkeld P.G., Bymaster F.P. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 2002, 27:949-959.
42. Richards J.B., Papaioannou A., Adachi J.D., Joseph L., Whitson H.E., Prior J.C., et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch. Intern. Med. 2007, 167:188-194.
43. Zamani A., Omrani G.R., Nasab M.M. Lithium's effect on bone mineral density. Bone 2009, 44:331-334.